Regeneron Antibody for Cat Allergies Met Endpoint in Phase 2
(Bloomberg) -- Regeneron’s antibody cocktail to treat cat-allergic patients with asthma met its primary endpoint in a Phase 2 study.
The investigational antibody prevented early asthma reactions and met key secondary endpoints by improving lung function and increasing the amount of cat allergen that the patients could tolerate following a single dose of the treatment.
To view the source of this information click here
©2021 Bloomberg L.P.